Cite
HARVARD Citation
Butt, A. et al. (2016). Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. Alimentary pharmacology & therapeutics. 44 (7), pp. 728-737. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Butt, A. et al. (2016). Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. Alimentary pharmacology & therapeutics. 44 (7), pp. 728-737. [Online].